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Abstract: Dietary lipids and some pharmaceutical lipid excipients can facilitate the targeted delivery
of drugs to the intestinal lymphatics. Here, the feasibility of magnetic resonance imaging (MRI) for
imaging lipid uptake into the intestinal lymphatics was assessed, shedding light on which lymph
nodes can be targeted using this approach. Three healthy male volunteers were scanned at 3.0 T at
baseline, 120, 180, 240, and 300 min post high-fat meal. A sagittal multi-slice image was acquired
using a diffusion-weighted whole-body imaging sequence with background suppression (DWIBS)
(pre inversion TI = 260 ms). Changes in area, major, and minor axis length were compared at each
time point. Apparent diffusion coefficient (ADC) was calculated (b = 0 and 600 s/mm2) across
eight slices. An average of 22 nodes could be visualised across all time points. ADC increased at
120 and 180 min compared to the baseline in all three participants by an average of 9.2% and 6.8%,
respectively. In two participants, mean node area and major axis lengths increased at 120 and 180 min
relative to the baseline. In conclusion, the method described shows potential for repeated lymph
node measurements and the tracking of lipid uptake into the lymphatics. Further studies should
focus on methodology optimisation in a larger cohort.
Keywords: intestinal lymphatic transport; lymph nodes; MRI; lipids; lipid-based formulations
1. Introduction
The intestinal lymphatic system is responsible for the absorption of dietary lipids
from the small intestine in the form of large lipoproteins assembled in the enterocytes
(chylomicrons). Drugs with specific physiochemical properties including LogD7.4 > 5 have
been shown to associate with chylomicrons. This means that they could avoid hepatic
first-pass metabolism though delivery to mesenteric lymph nodes, thus bypassing the
liver [1]. The use of lipid-based formulations to promote the formation of chylomicrons
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can further enhance lymphatic targeting. Using this delivery approach, it was shown
in rats that up to 250-fold times higher cannabinoid concentrations could be achieved
in lymph relative to plasma [2]. Furthermore, lymphatic uptake of drugs with poor
chylomicron association can be enhanced through the design of highly lipophilic prodrugs,
as recently demonstrated [3–5]. Although rats have fewer lymph nodes compared to
humans, the basic morphologic structure and rates of lipid transport to the mesenteric
nodes are comparable [6,7]. Based on this, it can be assumed that the lymph nodes of
human mesentery may also be targeted through the use of chylomicron-associated drugs.
In addition, efferent lymph from the mesenteric lymph nodes is understood to collect into
the retroperitoneal lymph nodes before entry into the cistern chyli and thoracic duct [8].
Retroperitoneal nodes may also be exposed to chylomicron-associated drugs. However,
to our knowledge, very few attempts have been made to quantify drug delivery to the
intestinal lymphatic system following oral delivery in humans [9]. With a growing interest
surrounding lymphatic targeting using lipid based formulations in the literature [10–12],
knowledge of which specific nodes can be targeted is essential for determining the clinical
potential of intestinal lymphatic drug targeting.
The intestinal lymph nodes are fundamental for response to external pathogens in the
diet [13]. They also play important homeostatic roles in intestinal interstitial fluid balance
and the uptake of dietary lipids. Unfortunately, the intestinal lymphatic system is also
central to a number of pathologies including inflammatory and autoimmune diseases,
infectious diseases, lymphomas, and cancer metastasis [12]. Cancer metastasis is widely un-
derstood to be responsible for around 90% of cancer-related morbidities [14] and lymphatic
involvement is commonly detectable at the time of primary tumour diagnosis. The primary
treatment for lymph node metastasis is lymphadenectomy surgery, in which the affected
lymph nodes are excised, usually followed by adjuvant chemotherapy or radiotherapy.
However, complexity surrounding the identification of sentinel nodes makes this difficult.
Subsequently, reoccurrence or unnecessary disruption in lymphatic flow resulting in pain
and oedema can occur [15]. In addition, the cytotoxic nature of most clinically relevant
chemotherapeutic drugs results in a range of associated adverse effects. Moreover, per-
meability into affected lymph nodes is often poor [4,16]. Therefore, drugs that specifically
target metastatic lymph nodes of the intestines have the potential for significant clinical
impact.
The number of metastatic nodes and distance from the primary tumour are major clin-
ical considerations in staging and subsequent prognosis [17]. In many cancers, the pattern
of lymph node metastasis from the primary tumours is well described and predictable.
Unsurprisingly, the first nodes in which oncological changes can be identified, termed the
sentinel node or nodes, are almost always those in closest proximity to the primary tumour.
Based on this, metastatic mesenteric lymph nodes are commonly described in gastric, small
intestine endocrine, and colorectal cancers [18]. More specifically, colonic carcinoma is the
third leading cause of cancer related death in the world [19] and MLN involvement was
described in 40% of patients with late stage colorectal cancer [20]. However, in addition
to GI tract related cancers, metastasis from primary tumours such as carcinomas in the
ovaries, oesophagus, appendix, breast, lung, pancreas, bladder, melanoma as well as Ka-
posi sarcoma following HIV infection has also been described in the mesenteric lymph
nodes [18]. This highlights the incomplete understanding of metastatic processes from
these areas. Knowledge to which lymph nodes the drug is delivered could prove to be
invaluable for informing which primary tumour metastases could be treated by intestinal
lymphatic targeting approach.
Imaging of the intestinal lymph nodes poses a number of difficulties including motion
due to peristalsis and respiration, their small size, and central location inside the body.
Imaging in the transverse plane has the benefit of allowing the nodes throughout the
mesentery that fan out to the left and right of the body to be imaged [1,15,18]. However, the
majority of superior mesenteric lymph nodes seen at imaging lie at the root of the superior
mesenteric artery (SMA) [21]. The SMA branches from the aorta lying along the spine at the
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first lumbar vertebra [22]. Therefore imaging in the sagittal plane allows for visualisation
of these nodes as well as those closely associated with the aorta. In addition, in house data
suggest that abdominal scanning in the sagittal plane reduces motion due to respiration,
resulting in a better quality image. Magnetic resonance imaging (MRI) in the sagittal plane
was recently described for the imaging of the intestinal lymph nodes in healthy human
volunteers [23]. In this work, several parameters were measured including lymph node
major and minor axis length and apparent diffusion coefficient (ADC), a measure of the
extent of water diffusion. Large lipid droplets have been observed in mesenteric lymph
nodes as a result of a high fat diet [24]. Based on this, it was hypothesised that lymph
nodes may increase in size as they receive lymph containing dietary lipids. In addition, as
the composition of lymph draining into lymph nodes becomes more lipid rich, it was also
hypothesised that the ADC may also change. Using these parameters as indications of lipid
uptake, the MRI method previously described, may thus allow for the identification of
nodes involved in lymphatic uptake of dietary lipids, lipid excipients, and co-administered
drugs.
In this work, we aimed to assess the feasibility of MRI for the repeated imaging of the
intestinal lymph nodes pre- and post-high fat meal. By analysing these lymph nodes, we
also aimed to access the potential of MRI methodology for imaging the distribution and
movement of lipids in the intestinal lymphatics. We discuss the relevance of this work in
identifying which lymph nodes may be targeted through intestinal lymphatic transport of
orally administered drugs and thus the clinical potential of this targeting approach.
2. Materials and Methods
The study protocol was approved by the University of Nottingham School of Medicine
and Health Sciences Research Ethics Committee, Queens Medical Centre, Nottingham,
University Hospitals, Nottingham, UK. (ref no. 358-1906). All subjects gave written
informed consent and had no contraindications to MRI.
2.1. Study Participants
All three participants were healthy male volunteers aged 25–30 years with no history
of underlying cardiac or gastro-intestinal disorders or symptoms. All participants had a
healthy BMI (between 18.5 and 24.9) and no food intolerances or allergies.
2.2. Study Design
Participants were asked to fast from 10 pm the evening prior to the MRI study day.
Water was allowed up until 2 h prior to scanning. Participants were scanned in the supine
position at fasted baseline and then 120, 180, 240, and 300 min after the consumption of a
high fat content meal. The meal consisted of 300 g creamed rice pudding uniformly mixed
with 25 g seedless raspberry jam and 30 g double cream, and a drink of 100 mL orange
juice with 240 mL of water (total energy content 518.8 kcal, fat content 18.5 g, carbohydrate
content 76.5 g, with a median gastric half-emptying time of 80 min [25]).
2.3. MRI Acquisition
All images were acquired using a Philips 3T Ingenia (Best, The Netherlands) with a
32 channel dStream torso coil (Philips Healthcare).
2.4. Lymph Node Imaging
The diffusion-weighted whole-body imaging with background suppression (DWIBS)
sequence was used to highlight the lymph nodes within the abdomen (pre inversion,
TI = 260 ms, for background suppression). A free breathing coronal DWIBS was first
acquired to gain a general idea of where nodes were located. Following this, a respiratory
triggered DWIBS was performed in the sagittal plane to reduce through plane motion.
Eight imaging slices were acquired at each time point, with 2.5 × 2.5 × 4.68 mm3 voxels,
reconstructed to 1.56 × 1.56 mm2 in-plane resolution and a slice thickness of 4.68 mm with
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0 mm gap between them (time to echo (TE) = 75 ms, inversion time (TI) = 260 ms, repetition
time (TRmin) = 3000 ms, sensitivity encoding (SENSE) factor 2.3).
It was hypothesised that as the lymph nodes that receive lipids from the meal, they
would physically swell, causing an increase in size. Three parameters (area, major axis,
and minor axis) were recorded in an attempt to characterise any changes in lymph node
size following the high fat meal. The number of lymph nodes visible at each time point
was also compared in order to assess whether some lymph nodes which in the fasted state
were not visible, then be-came visible, as they receive lipids.
It was also hypothesised that ADC may change as the lymph nodes receive lipid rich
lymph from the intestine. Two diffusion weightings (b = 0 and 600 s/mm2) were used to
measure ADC across the eight slices.
2.5. Gastric Volume (T2)
Gastric emptying and small bowel water were also measured to monitor the progres-
sion of lipids through the GI system. Gastric volumes were determined using a coronal
Half-Fourier Acquisition Single-shot Turbo spin Echo (HASTE) sequence. Twenty eight
slices were acquired at each time point with 1.4 × 1.7 × 5 mm3 voxels reconstructed
to 1 × 1 mm2 in plane resolution with a slice thickness of 5 mm and slice gap of 1 mm
(TE = 96 ms, TR = 1262, SENSE factor 2.0).
2.6. Small Bowel Water Content (SBWC)
SBWC was determined using a single shot, fast spin echo sequence (Rapid Acquisition
with Relaxation Enhancement, RARE) as previously described [26]. Briefly, 20 coronal slices
(7 mm slice thickness, no gaps in-between slices, 0.78 mm × 0.78 mm in-plane reconstructed
resolution) were acquired in a single breath hold (TR = 1169 ms, TE = 400 ms, acquired
resolution = 1.4 mm × 1.76 mm, SENSE factor 2).
2.7. Data Analysis
For each lymph node, a region of interest (ROI) was drawn around the periphery of
the node on the two diffusion weighted images using Medical Image Processing, Analysis
and Visualization software (Version 9.0.0, National Institutes of Health) [27]. Area, major,
and minor axes were calculated. The signals from the two b value images were used to
calculate ADC using the formula ADC = −1/b600ln(S(b600))/S(b0)). Where a lymph node
could be consistently imaged across all time points, the % change in each parameter relative
to baseline per lymph node was calculated. This allowed for changes in smaller lymph
nodes to be equally represented.
The position of each lymph node in terms of vertebra level was also recorded in an
attempt to assess which lymph nodes were being imaged [8].
The gastric volumes were calculated by drawing a region of interest around the bright
content of the stomach in MIPAV on the T2 weighted dataset. The total volume was a sum
of the volumes measured from each of the image slices. SBWC measurement was analysed
with in-house software that was previously described and validated [28].
The reproducibility of data acquired from ROIs drawn in MIPAV was determined by
drawing ROIs around the same randomly selected 15 nodes three times respectively (one
node per time point per participant). All repeats were performed by the same observer.
All figures were generated using GraphPad Prism version 7.0d (San Diego, CA, USA).
3. Results
3.1. Lymph Node Imaging
Gastric volume and SBWC were measured at several time points following the high
fat meal in order to understand when lipids may be entering the intestinal lymphatics
for each individual. In one participant, gastric volume was largely unchanged across all
time points. However, in the other two participants, an increase in gastric volume was
observed at 120 min post-meal (Figure 1). Gastric volume appeared to then be reduced
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to approximately baseline equivalent volumes at 180 min post-meal (Figure 1). Similarly,
SBWC initially appeared to decrease in all subjects as a result of nutrient-driven fluid
absorption [26]. This was followed by an increase at 180–120 min post-meal (Figure 1).
Based on this, it was predicted that lipid uptake into the lymphatics would be the greatest
after 120 min post-meal.
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4. Discussion
The aim of this feasibility study was to establish whether MRI could be utilised to
image the intestinal lymph nodes of healthy human volunteers at multiple time-points
pre- and post-meal. Through repeat measurements of various parameters such as lymph
node size and ADC, the feasibility of this method to identify changes in intestinal lymph
nodes following the ingestion of a fatty meal was also assessed. Measurable changes in
lymph nodes following lipid uptake could then be exploited to track the movement of
lipids and drugs through the lymphatic system and inform which lymph nodes could be
targeted using orally administered lipid-based formulations. To our knowledge, this work
represents the first attempt to perform longitudinal imaging of the intestinal lymph nodes
and measure lipid induced changes to lymph nodes in healthy human volunteers.
Data in the current study suggest that abdominal lymph node major and minor axes
lengths may increase with the uptake of lipids. Larger changes relative to baseline were
observed when comparing lymph node area than when comparing major and minor axes
lengths. Area may therefore be a more sensitive measure for monitoring lipid uptake
than axis length. This could be because both changes in major and minor axes lengths are
simultaneously reflected in the area. ADC was the only parameter to consistently change
across all participants. Increases in ADC were highest at 120 and 180 min post-meal, which
encouragingly correlated with our time scale predictions on gastric volume and SBWC.
Therefore, ADC may also be used to indicate lipid uptake into lymph nodes in future
studies.
Using the MRI method described here, the vertebra of the spine could be used as
an anatomical marker to allow for the repeated imaging of individual lymph nodes. The
majority of the nodes imaged were positioned slightly anterior to the centre of the spine
between the second and third lumbar vertebra. Based on their location, these nodes are
most likely to be retroperitoneal nodes, more specifically the preaortic nodes. In some scans,
nodes were visible closer to the spine and therefore more likely to be the retroaortic nodes.
In addition, a small number of nodes were located between the fourth and fifth vertebra
and likely to be the iliac nodes. Further imaging of these nodes in future work may help
determine whether they can be targeted using a lipid-based formulation approach [8,29].
Lymph node imaging is routinely performed in the clinic to identify abnormalities
that may indicate metastatic involvement from a primary tumour [30–32]. More recently,
monitoring lymph node enlargement and necrosis have also been implemented in the
staging and prognosis of inflammatory diseases such as Crohn’s disease and ulcerative
colitis [23]. Several different methods have been employed for imaging lymph nodes
including ultrasound, positron emission tomography (PET), computed tomography (CT),
and contrast agent enhanced MRI [30]. These methods rely on the ability to detect changes
in size or morphology, or in the case of 18F-FDG PET, altered physiological function. A
number of studies have demonstrated that PET/CT fusion is more sensitive and accurate
for lymph node staging than conventional CT [30]. However, the requirements for altered
physiological function as well as exposure of the individual to radiation make these
methods inappropriate for longitudinal imaging lymph nodes in healthy volunteers. In
addition, for the purposes of this study, the use of contrast-enhanced MRI was ruled out on
the basis that it requires IV or subcutaneous administration and is therefore not optimal for
imaging in healthy human volunteers. Based on this, the major benefit of the MRI method
described here is its non-invasive, label-free approach. This makes MRI a key tool for the
serial scanning of healthy volunteers.
A number of approaches could improve the method sensitivity for detecting lipid-
induced changes in lymph nodes. First, in terms of study design, the preliminary nature
of this work means a small cohort of participants were included. Having indicated the
feasibility of this method for tracking lymphatic uptake of lipids, more data from a larger
number of participants would provide statistical power in future studies and thus aid
conclusions about which lymph nodes can be targeted using lipid-based formulations.
There is also substantial variability in the data for all parameters measured and although an
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initial appraisal of this is one of the findings of this feasibility study, future work with larger
sample sizes will also allow for a more detailed assessment of this. More specifically, inter-
participant differences in gastric emptying times were observed. Based on this, differences
in the rates of lipid uptake into the lymphatics are also likely and so more personalised
scanning intervals may ensure that differences are not being missed. Similarly, combining
scanning with simultaneous blood sampling to determine triglyceride content would also
provide indications of lipid entry into systemic circulation and subsequent flow out of the
lymphatic system. In addition, in an attempt to enhance lipid uptake, the lipid content
of the meal or formulation could be adjusted to include a higher lipid content. This may
include ong-chain triglycerides, which have been shown in preclinical studies to enhance
lymphatic uptake [33]. This, however, would require additional gastric emptying time
data, which would likely be delayed as a result and may pose problems with palatability.
Improvements in imaging quality could also enhance the sensitivity of the proposed
MRI imaging approach. Inevitably, as with most imaging techniques, a compromise
between resolution and background noise is required. Although more invasive for par-
ticipants, the use of an intravenous administration of an anticholinergic agent such as
butylscopolamine could be utilised to prevent movement from peristalsis, which is known
to decrease image quality [34]. Finally, although the vertebra of the spine was useful in
identifying individual lymph nodes across each scan, the use of external markers to ensure
consistent imaging planes would also be beneficial in future studies. A control scanning
set in the fasted state, following water only, or alternatively following a meal with equal
calories but no lipids, could also be useful to determine background fluctuations in lymph
node parameters in the absence of lipids.
5. Conclusions
The purpose of this study was to assess the feasibility of MRI for repeated imaging of
the intestinal lymph nodes in healthy volunteers, pre- and post-high fat meal. Individual
lymph nodes could be repeatedly imaged at multiple time points. These data also suggest
that postprandial increases in lymph node size and ADC could be observed. Based on
this, the MRI methodology described represents a safe and label-free approach that shows
promise for tracking the movements of lipids through the intestinal lymphatic system and
interaction with immune cells. The method may therefore be used to inform which lymph
nodes can be targeted using orally delivered lipid-based formulations. Future work should
focus on ensuring the reproducibility in a larger participant cohort as well as optimisation
of the methodology.
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